Insulin-Sensitizing Therapy Attenuates Type 2 Diabetes–Mediated Mammary Tumor Progression
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Type 2 diabetes increases breast cancer risk and mortality, and hyperinsulinemia has been identified as a major factor linking these two diseases. Thus, we hypothesized that pharmacological reduction of elevated insulin levels would attenuate type 2 diabetes–mediated mammary tumor progression. RESEARCH DESIGN AND METHODS: We studied mammary tumor development in MKR+/+ mice, a nonobese, hyperinsulinemic mouse model of type 2 diabetes. MKR+/+ mice were either crossed with mice expressing the polyoma virus middle T oncogene specifically in the mammary gland or inoculated orthotopically with the mouse mammary tumor cell lines Met-1 and MCNeuA. MKR+/+ or control mice harboring tumors were treated with CL-316243, a specific β3-adrenergic receptor agonist, which sensitizes insulin action but has no direct effect on the mouse mammary epithelium or Met-1 and MCNeuA cells. RESULTS: CL-316243 treatment significantly reduced the elevated insulin levels in MKR+/+ mice and, as a consequence, attenuated mammary tumor progression in the three tumor models tested. This effect was accompanied by reductions in phosphorylation of insulin and IGF-I receptors in transformed mammary tissue. CONCLUSIONS: Insulin-sensitizing treatment is sufficient to abrogate type 2 diabetes–mediated mammary tumor progression. Therefore, early administration of insulin-sensitizing therapy may reduce breast cancer risk and mortality in patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613 · cited 1×
“However, in the setting of excess energy intake and obesity, other factors besides hyperinsulinemia can promote tumor growth, such as adipokines, proinflammatory cytokines, adipose tissue–derived sex steroids, or altered levels of circulating carbohydrates and lipids (43), some of which may be affected by metformin tr…”
BackgroundMetformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 1×
“There is growing evidence that antidiabetic therapy elevating insulin levels increases cancer risk as well as cancer-related mortality (8,9), whereas insulinsensitizing drugs may reduce cancer risk, morbidity, and mortality (8–14) in patients with type 2 diabetes.”
BackgroundKirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084 · cited 1×
“However, in the setting of excess energy intake and obesity, other factors besides hyperinsulinemia can promote tumor growth, such as adipokines, proinflammatory cytokines, adipose tissue–derived sex steroids, or altered levels of circulating carbohydrates and lipids (43), some of which may be affected by metformin tr…”
BackgroundMetformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Barone, B. B. (2008) · JAMA · doi:10.1001/jama.2008.824 · Cited by 881
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880
Cited by
Molecular mechanisms of cancer development in obesity
Khandekar, M. J., Cohen, P., & Spiegelman, B. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3174 · Cited by 907
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806
“Reducing insulin levels in the MKR mice using a -3 adrenergic receptor agonist (CL-316,243) or blocking the IR and IGF-IR using a tyrosine kinase inhibitor reduced the growth of the primary tumors in the female MKR mice; conversely, administration of a mitogenic insulin analog increased tumor growth and metastases in…”
BackgroundMethodSelf-citationHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Self-citationAMPK As a Metabolic Tumor Suppressor: Control of Metabolism and Cell Growth
Luo, Z., Zang, M., & Guo, W. (2010) · Future Oncology · doi:10.2217/fon.09.174 · Cited by 383
The proliferating role of insulin and insulin-like growth factors in cancer
Gallagher, E. J., & LeRoith, D. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.06.007 · Cited by 380
Self-citationMinireview: IGF, Insulin, and Cancer
Gallagher, E. J., & LeRoith, D. (2011) · Endocrinology · doi:10.1210/en.2011-0231 · Cited by 349
Self-citationObesity, type 2 diabetes, and cancer: the insulin and IGF connection
Cohen, D. H., & LeRoith, D. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-11-0374 · Cited by 301
Self-citationNuclear receptors outside the nucleus: extranuclear signalling by steroid receptors
Levin, E. R., & Hammes, S. R. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.122 · Cited by 277
Belfiore, A., & Malaguarnera, R. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0074 · Cited by 272
Obesity, Type 2 Diabetes, and Cancer Risk
Scully, T., Ettela, A., LeRoith, D., & Gallagher, E. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.615375 · Cited by 256
Self-citationGallagher, E. J., & LeRoith, D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0295-5 · Cited by 241
Self-citationMammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model
Alikhani, N., Ferguson, R. D., Novosyadlyy, R., Gallagher, E. J., Scheinman, E. J., Yakar, S., & LeRoith, D. (2013) · Oncogene · doi:10.1038/onc.2012.113 · Cited by 146
Self-citationDietary energy restriction reduces high-fat diet-enhanced metastasis of Lewis lung carcinoma in mice
Sundaram, S., & Yan, L. (2016) · Oncotarget · doi:10.18632/oncotarget.11598 · Cited by 13
Metadata
- Authors
- Fierz, Y., Novosyadlyy, R., Vijayakumar, A., Yakar, S., & LeRoith, D.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-12-03
- Volume
- 59
- Issue
- 3
- Pages
- 686-693
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2028639140
- Cited by
- 92
- References
- 17
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.